



National Securities Market Commission
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Colmenar Viejo (Madrid), January 24, 2019

Pursuant to Article 17 of Regulation (EU) n° 596/2014 on market abuse and Article 226 of the consolidated text of the Spanish Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, we hereby make the following REGULATORY ANNOUNCEMENT:

“Pharma Mar, S.A. announces that the Committee for Orphan Medicinal Products (COMP), from the EMA, has given its positive opinion for the approval of Orphan Drug status to Zepsyre® (lurbinectedin) for the treatment of small-cell lung cancer. Zepsyre® is at a phase III investigational stage for the treatment of this type of tumour. Please find attached press release that Pharma Mar, S.A. will distribute to the media”.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com

PharmaMar receives positive opinion from EMA (COMP) for orphan drug designation of Zepsyre® (lurbinectedin) for small-cell lung cancer

Madrid, 24 of January, 2019. PharmaMar (PHM:MSE) announces that the Committee for Orphan Medicinal Products (COMP), from the EMA, has given its positive opinion for the approval of Orphan Drug status to Zepsyre® (lurbinectedin) for the treatment of small-cell lung cancer.

Small-cell lung cancer is PharmaMar's current priority research area. Zepsyre® (lurbinectedin) is at the Phase III investigational stage, with its ATLANTIS study for the treatment of this type of tumour. PharmaMar finalised recruitment in July 2018, and hopes to have the final data on overall survival during the second half of 2019.

PharmaMar expects to release the Zepsyre® (lurbinectedin) Phase II monotherapy data for relapsed small-cell lung cancer in the first half of 2019 and to submit it for presentation it at a future medical meeting.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at www.pharmamar.com.

About lurbinectedin

Lurbinectedin (PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127

Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464

Phone: +34 918466000



Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com